Background: The chromogenic anti-Xa assay, the gold standard for monitoring the
| INTRODUCTION
Despite the need for anticoagulants in companion animals, there have been some limitations with the use of anticoagulant agents in veterinary medicine. Agents such as warfarin, a PO administered anticoagulant, are rarely used in veterinary medicine because of safety issues, and heparin is available only in injectable form, which makes it difficult for animal owners to manage long-term treatment.
Recently, newly developed PO direct factor Xa anticoagulants were approved for the treatment of thrombosis in human patients.
These anticoagulants have wide safety margins, making them safer for use than earlier anticoagulants. Rivaroxaban is a novel PO direct factor Xa anticoagulant that decreases the risk of stroke and systemic embolism in human patients with nonvalvular atrial fibrillation and also is used for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism. [1] [2] [3] [4] Unfortunately, rivaroxaban has not been widely used in clinical settings in veterinary medicine. 2, 4 Rivaroxaban exerts its anticoagulant effect by directly inhibiting activated factor Xa. Therefore, the assay to evaluate the activity of factor Xa can be used to evaluate plasma rivaroxaban concentration indirectly. The assay measures the amount of active Xa using a chromogenic substrate, and the absorbance is inversely proportional to the rivaroxaban concentration. This assay, commonly referred to as "chromogenic anti-Xa assay," is considered a suitable method for monitoring the effect of rivaroxaban, [5] [6] [7] but this test is impractical in veterinary medicine because of its limited availability.
In human medicine, prothrombin time (PT) can be an alternative measurement to plasma rivaroxaban concentration for monitoring treatment and is a more accurate strategy for assessing rivaroxaban than is activated partial thromboplastin time (aPTT). 6, [8] [9] [10] Variations in sensitivity were reported when different PT reagents were used. Modification of PT measurement has been proposed to enhance sensitivity and decrease reagent variability. 6, 7, 11, 12 Unlike in human medicine, alternative measurements of rivaroxaban concentration for therapeutic monitoring in veterinary medicine have not been reported.
Thromboelastography (TEG) is a viscoelastic hemostatic assay that
measures the global viscoelastic properties of whole blood clot formation. 11 In a previous study, TEG using different strong activators was used to monitor unfractionated heparin treatment in dogs. 13 Evaluating the effect of rivaroxaban in blood using TEG appears promising 11,14 but may yield variable results with different activators.
Rivaroxaban could be a more attractive long-term therapeutic option for outpatients with thrombotic diseases than is warfarin because it previously has been reported to have higher PO bioavailability (60%-86%) in dogs. 15 
| Drug administration
Commercially available 20 mg rivaroxaban tablets (Xarelto 20 mg tablets; Bayer HealthCare AG, Leverkussen, Germany) were split using a pill cutter and then administered to the dogs. Single PO doses of rivaroxaban at 0.5, 1, 2, and 4 mg/kg were administered to 6 dogs with a 2-week washout period between the different dosages. To detect residual activity and cumulative effect of rivaroxaban, 0.5 and 1 mg/kg rivaroxaban were administered to 3 randomly selected dogs every 24 hours for 3 consecutive days. The dogs were not fasted and were evaluated twice daily during the study for any adverse effects. General physical examination and signs of bleeding were evaluated.
| Sample collection
For the single PO dose trials, blood samples were collected before and 3 hours after each dose administration. Six milliliters of blood were drawn from the jugular vein using 10-mL plastic syringes with 18G (38 mm) needles (Jungrim Medical, Korea). The blood was transferred into 3 3.2% sodium citrate tubes (Vacuette, 3.2% sodium citrate, 2-mL tubes; Greiner Bio-One, Kremsmünster, Austria) with a final citrate :
blood ratio of 1 : 9.
One day before drug administration, 3 randomly selected dogs each in the 0.5 and 1 mg/kg dosage trial groups were given 0. 
| Analysis of blood samples
Citrated whole blood was used to perform PT and TEG analyses. The PT was evaluated within 2 hours of blood collection using a point-ofcare device and cartridges for point-of-care PT devices were used after a 30-minute rest period at room temperature. Citrated whole blood samples were used for TEG after a 30-minute rest period at room temperature. The TEG analysis was performed within 2 hours of blood collection using the recalcification method with 4 different activators When strong activators such as RapidTEG and TF100 were used, the R value results were obtained within minutes because these agents have strong activating properties. Thus, the R value results were set to seconds rather than minutes for precise analysis when >150 ng/mL were reassessed at 1 : 20 dilution using the high calibrator set (Technoview Rivaroxaban CAL High Set). The assay was performed in 96-well microtiter plates in duplicate, and the absorbance was read at 405 nm with 620 nm as the reference wavelength using a microplate reader (VersaMax, Molecular Devices, Boston, Massachusetts). The detection limit for rivaroxaban in this assay was 10 ng/mL.
The EDTA blood samples were processed to obtain PCV, total protein concentration, platelet count, and fibrinogen concentration. Total protein concentrations were measured using a refractometer. Platelet counts were determined using an automated analyzer (Procyte Dx hematology analyzer). The fibrinogen concentration was measured using a semiquantitative heat precipitation method. 21 
| Statistical methods
The commercially available statistical package for the social sciences (SPSS) software (version 23.0; SPSS, Chicago, Illinois) was used to generate descriptive statistics. The normality of the data was tested using the Kolmogorov-Smirnov test. The parametric data were presented as the means ± SD, whereas the nonparametric data were presented as medians (range). The normally distributed (parametric) data were analyzed using a 1-way analysis of variance when there were ≥3 groups.
When the data distribution was skewed (nonparametric), the Kruskal- 3 | RESULTS
| Rivaroxaban concentration determined using chromogenic anti-Xa assay and its adverse effects
Rivaroxaban increased peak plasma anti-Xa concentration (averaged) at 3 hours after drug administration (P < .001 versus baseline, Figure 1A ), and the increment in plasma anti-Xa concentration was dose-dependent (Spearman's correlation coefficient R = 0.84; Figure 1C and Table 1 ). However, the dose-effect relationship was not proportional among dogs, and interindividual differences in drug effects were significant ( Figures 1B, D) . The between-subject coefficients of variation were 39.5% (0. (Table 2 ). 
| Effect of rivaroxaban on PT and TEG parameters

| DISCUSSION
We showed that PO rivaroxaban administration has predictable anticoagulant effects with high interindividual variability. Anti-Xa concentration peaked at 3 hours after drug administration. The statistical correlations between the anti-Xa concentrations peaked at 3 hours after drug administration, and TEG and PT results showed that values and ratios of PT, R, and SP of TEG were strongly correlated with anti-Xa concentration when RapidTEG, TF100, and TF3700 were used. Rivaroxaban was well tolerated by healthy dogs, and no adverse effects were noted.
Rivaroxaban shows predictable drug effects in humans, thus monitoring drug effects in general is not necessary. However, interindividual variability still is a factor, and some studies have recommended monitoring drug effects in humans. [23] [24] [25] [26] [27] Although average peak antiXa concentration at 3 hours after drug administration was observed, interindividual variability was observed despite the small number of animals in our study. One dog (dog E in Figure 1 ) showed relatively T A B L E 1 Anti-Xa concentration, prothrombin time (PT), and reaction time (R) value of thromboelastography (TEG) at baseline (0 hours) and peak time (3 hours) in dogs treated with 4 different doses of rivaroxaban *Statistically significant differences (P < .05) between baseline and peak time were noted. RapidTEG, TF100, TF3700, and kaolin are activators of TEG.
Results are presented as median (range).
T A B L E 2 PCV, total protein, platelets, and fibrinogen concentration at baseline, 12 hours, and final time point Results are presented as mean ± SD if data distribution was parametric or median (range) if data distribution was skewed.
low increments in PT and TEG parameters as well as anti-Xa concentration after drug administration. These results are similar to those of a previous study that reported that interindividual variability was moderate to large in 24 healthy Beagles. 14 We speculate that individual monitoring of rivaroxaban in dogs could be beneficial, unlike in humans, and appropriate individual dosage adjustment could be achieved by PT and TEG monitoring according to the study.
Previous studies in dogs have reported a mild to moderate interindividual variability, and the dosage could be appropriately adjusted by interpreting the PT results in a clinical setting. 4, 14 Although the exact reason is not known, interindividual variability also was detected in our study. However, the same individual showed similar anticoagulant effects with the same repeated dosing in the 3-day consecutive dosing trial.
Thus, dosage adjustments may be required to achieve similar anticoagulant effects in individual animals. This variation may have been affected by gastrointestinal drug absorption and genetic polymorphism in drug metabolism. 23 Rivaroxaban has a lower affinity for canine factor Xa than for human factor Xa, and this difference may affect interindividual variability. 28 In terms of peak time, peak plasma activity of rivaroxaban was reached 2-4 hours after administration in humans. 29 We selected 3 hours post-administration as the peak time point according to previous studies in humans. 10, 22 A recent study reported a peak time point of 1.5-2 hours after dosing in dogs. 14 However, the dogs in our study
were not allowed to fast during the study period; thus, the peak time may have been slightly delayed because food can interfere with the absorption of rivaroxaban, leading to delayed peak times of 0.5-1.5 hours compared to those in the fasted state. 24 We attempted to simulate actual situations of clinical drug administration and therefore the dogs were not fasted. In addition, the drug effect was detected 3 hours after dosing in various tests but not 8 or 12 hours after dosing using the point-of-care PT and TEG devices. This result was similar to results of a previous study.
14 Three dogs each in the 0.5 and 1 mg/kg dosing groups were given rivaroxaban once daily for 3 consecutive days and were monitored.
No cumulative effect was observed at these dosages, but statistical power was low because of the small numbers of animals per group.
To monitor responses to the rivaroxaban administration, the relationship between ratio values (PT and TEG) and anti-Xa concentration was plotted, followed by calculation of therapeutic ranges of ratio values using the least square method according to previous reports of unfractionated heparin. 13, 30 The plasma anti-Xa concentration range of 140-260 ng/mL was considered an effective thromboprophylactic antiXa concentration range of rivaroxaban in studies of humans. anti-Xa activity for the quantification of rivaroxaban plasma concentration. 12, 28, 29 A chromogenic assay was used in our study based on the methodology previously described. 20 Nonetheless, a standard curve was generated using frozen dried human plasma, not canine plasma, from the commercial chromogenic anti-Xa kit that we used. Thus, this could be a major limitation of our study.
In our study, dosages above 2 mg/kg were appropriate for healthy dogs to achieve an anti-Xa concentration >140 ng/mL at the peak time.
This dosage was similar to the appropriate dosage regimen suggested in a previous report. PT ratio RapidTEG-R ratio TF100-R ratio TF3700-R ratio Kaolin-R ratio Therapeutic ranges for ratio values were determined using linear regression equation corresponding to plasma anti-Xa concentration of 140-260 ng/mL. *P < .001.
T A B L E 3 Spearman's correlation coefficients between plasma anti-Xa concentration and thromboelastography (TEG) parameters using 4 different activators: RapidTEG; TF100; TF3700, and kaolin Kaolin-activated TEG showed the weakest correlation with plasma anti-Xa concentration. These results were thought to have occurred because PT analysis using tissue factor as a reagent showed a stronger correlation than that shown by aPTT analysis using surface activators as reagents. Among the various TEG parameters, R, SP, TMRTG, and TEG activated clotting time (ACT) were sensitive, with R being the most sensitive. The R value is a major parameter for detecting coagulation cascade abnormality, and R may have been the most sensitive because rivaroxaban directly inhibits coagulation factor X. The novel TEG parameter delta (difference between R and SP), which allows the differentiation of enzymatic and platelet hypercoagulability, also was calculated for each test. 38, 39 However, delta showed poor correlation with the plasma anti-Xa concentration (Table 3 ). The TEG-ACT also was calculated when
RapidTEG was used as an activator, and this parameter showed a strong correlation with conventional ACT devices. 40 However, TEG-ACT did not show superior results to those of the R value in our study ( Table 3 ).
The correlation analysis included baseline (0, 24, and 48 hours) and peak (3, 27, and 51 hours) time points of the 3-day consecutive dosing trial. However, the Spearman correlation significantly decreased when we included the 8 and 12 hours time points (8, 12, 32, 36, 56 , and 60 hours) of the 3-day consecutive dosing trial. This result was thought to be a consequence of decreases in plasma rivaroxaban concentration below the detection limit of the PT and TEG devices. Thus, a comparison of baseline and peak time point is reasonable for clinical monitoring of rivaroxaban.
The advantages of clinical therapeutic monitoring of rivaroxaban include the following: (i) optimal and effective dose regimens can be determined for each individual immediately; (ii) rivaroxaban is mainly excreted by renal and biliary routes, 15 and patients with decreased renal function or cholestasis, and those that are critically ill may benefit from therapeutic drug monitoring for safety 4, [41] [42] [43] ; and, (iii) administration of crushed tablets with other medications could cause drug-drug interactions and clinical monitoring could be used to assess the effectiveness of anticoagulation in such situations. 43 Our study had some limitations. First, a small number of dogs per group was used. Second, rivaroxaban was only tested in healthy Beagle dogs. Third, the therapeutic ranges of plasma anti-Xa concentration were extrapolated from studies of humans. Further research In conclusion, individual differences in drug effects were identified.
Thus, rivaroxaban treatment in dogs may be improved by clinical monitoring methods. Prolongation of PT and R value in TEG using a tissue factor or RapidTEG as an activator showed significant correlations with anti-Xa concentration of rivaroxaban. Furthermore, 1.5-1.9 × delayed results of the PT and R value of TEG 3 hours after administration would be required to achieve the proposed therapeutic anti-Xa concentrations based on studies in humans. This method is practical and can be used for individual dosage adjustment to decrease adverse effects and achieve proper anticoagulant effects. Further studies are warranted in critically ill patients to determine whether clinical outcome is different when therapeutic plasma concentrations of rivaroxaban are achieved using pointof-care PT and TEG activated with tissue factor or RapidTEG as a monitoring method.
